<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03476369</url>
  </required_header>
  <id_info>
    <org_study_id>1801-05</org_study_id>
    <nct_id>NCT03476369</nct_id>
  </id_info>
  <brief_title>Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention</brief_title>
  <acronym>FACTPCI</acronym>
  <official_title>A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Guthrie Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Guthrie Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation.
      Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study
      has demonstrated the decrease in effectiveness of Ticagrelor when administered along with
      Fentanyl. Hence this study was designed to further assess the interaction between crushed vs
      non crushed Ticagrelor and Fentanyl given during PCI procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Function Testing</measure>
    <time_frame>12 hours</time_frame>
    <description>Platelet vasodilator-stimulated phosphoprotein assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent myocardial infarction</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI minor and major</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Fentanyl and Crushed Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl and Non-crushed Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Premedicated with Fentanyl (at least 25mcg by IV)</description>
    <arm_group_label>Fentanyl and Crushed Ticagrelor</arm_group_label>
    <arm_group_label>Fentanyl and Non-crushed Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90Mg Tablet</intervention_name>
    <description>Ticagrelor administered crushed vs non-crushed</description>
    <arm_group_label>Fentanyl and Crushed Ticagrelor</arm_group_label>
    <arm_group_label>Fentanyl and Non-crushed Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing clinically indicated elective or non-elective PCI

          -  Able to swallow oral medications

        Exclusion Criteria:

          -  Contraindications to ticagrelor or fentanyl (or other opiates)

          -  Pregnancy

          -  Any use of P2Y12 inhibitors within 14 days

          -  Known coagulation disorders

          -  Pre-procedural treatment with an anticoagulant (oral anticoagulant or low molecular
             weight heparin)

          -  Platelet count &lt; 100,000/mm3

          -  Impaired renal function (Estimated glomerular filtration &lt; 45 ml/min/1.73 m2)

          -  Impaired hepatic function (Based on medical history)

          -  Prior or planned transcatheter aortic valve replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sudhakar Sattur, MD</last_name>
    <phone>570-887-6072</phone>
    <email>Sudhakar.Sattur@guthrie.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Guthrie Clinic</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicky Hickey</last_name>
      <phone>570-887-4882</phone>
      <email>Vicky.Hickey@guthrie.org</email>
    </contact>
    <investigator>
      <last_name>Sudhakar Sattur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2018</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

